Abstract
Fleischer CN Kotey, Alex Odoom, Samuel Darkwah, Raphael K. Yeboah, Nicholas T. K. D. Dayie
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
No local reference links have been materialized yet.
Multidrug-Resistant Bacteria in Hospital Wastewater of the Korle Bu Teaching Hospital in Accra, Ghana
2022
10.1371/journal.pone.0279715
10.1371/journal.pone.0279715
Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis
10.1016/s0140-6736(21)02724-0 · 2022
10.3390/antibiotics12020255
10.3390/antibiotics12020255
Methicillin-Resistant Staphylococcus aureus in the oral cavity: Implications for antibiotic prophylaxis and surveillance
2020
10.1371/journal.pone.0283706
10.1371/journal.pone.0283706
In vitro antimicrobial activity of crude propolis extracts and fractions
10.1093/femsmc/xtad010 · 2023
Evaluation of separation and purification processes in the antibiotic industry
10.1007/bf02930830 · 1988
Coprophilous fungi: Antibiotic discovery and functions in an underexplored arena of microbial defensive mutualism
10.1016/j.mib.2013.08.001 · 2013
Exploitation of fungal biodiversity for discovery of novel antibiotics
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
10.1007/82_2016_496 · 2016
Bacterial viruses against viruses pathogenic for man?
10.1016/j.virusres.2005.01.009 · 2005
Unexploited opportunities for phage therapy
10.3389/fphar.2015.00180 · 2015
Current challenges and future opportunities of phage therapy
10.1093/femsre/fuaa017 · 2020
The pan-immune system of bacteria: Antiviral defense as a community resource
10.1038/s41579-019-0278-2 · 2020
10.1007/978-3-030-26736-0
10.1007/978-3-030-26736-0
10.3390/v10070351
10.3390/v10070351
Bacteriophage resistance mechanisms
10.1038/nrmicro2315 · 2010
Antibiotics: Past, present and future
10.1016/j.mib.2019.10.008 · 2019
10.3390/antibiotics8020045
10.3390/antibiotics8020045
Do we really understand how antibiotics work?
2020
Penicillin-resistant pneumococcus and risk of treatment failure in pneumonia
10.1136/adc.2006.111625 · 2008
Clinical characteristics of pneumococcal bacteremia in adults: The effect of penicillin resistance on the mortality of patients with pneumococcal bacteremia
10.4046/trd.1999.47.2.184 · 1999
Focus: Drug development: Penicillin’s discovery and antibiotic resistance: Lessons for the future?
2017
Antibiotic resistance profiling and phenotyping of Aeromonas species isolated from aquatic sources
10.1016/j.sjbs.2015.09.016 · 2017
The antibiotic resistance crisis: Part 1: Causes and threats
2015
10.3390/pathogens11121517
10.3390/pathogens11121517
Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe
10.2807/ese.13.47.19045-en · 2008
Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections
10.1128/cmr.00031-19 · 2019
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Antimicrobial stewardship: Fighting antimicrobial resistance and protecting global public health
10.2147/idr.s290835 · 2020
Unresolved referenced work
Kept as external metadata until matched
Phage therapy of pulmonary infections
10.1080/21597081.2015.1020260 · 2015
Early clinical experience of bacteriophage therapy in 3 lung transplant recipients
10.1111/ajt.15503 · 2019
Phage therapy for respiratory infections
10.1016/j.addr.2018.08.001 · 2018
Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: A case report
10.1016/j.resmic.2018.05.001 · 2018
10.1007/978-3-030-03077-3
10.1007/978-3-030-03077-3
Bacteriophage therapy of chronic nonhealing wound: Clinical study
10.1177/1534734619835115 · 2019
13 Phage Therapy of Wounds and Related Purulent Infections
2012
10.3390/antibiotics8040182
10.3390/antibiotics8040182
Bacteriophage therapy: A regulatory perspective
10.1093/jac/dkw083 · doi-reference
Phage Therapy in Clinical Practice: Treatment of Human Infections
10.2174/138920110790725401 · doi-reference
Biofilm susceptibility to bacteriophage attack: The role of phage-borne polysaccharide depolymerase
10.1099/00221287-144-11-3039 · doi-reference
Phage cocktails and the future of phage therapy
10.2217/fmb.13.47 · doi-reference
10.1371/journal.pone.0124280
10.1371/journal.pone.0124280 · doi-reference
10.1371/journal.pone.0031698
10.1371/journal.pone.0031698 · doi-reference
Bacteriophage treatment of intransigent diabetic toe ulcers: A case series
10.12968/jowc.2016.25.7.s27 · doi-reference
10.3390/v11040352
10.3390/v11040352 · doi-reference
Bacteriophage-based synthetic biology for the study of infectious diseases
10.1016/j.mib.2014.05.022 · doi-reference
10.3390/ijms21124390
10.3390/ijms21124390 · doi-reference
Environmental Phage-Based Cocktail and Antibiotic Combination Effects on Acinetobacter baumannii Biofilm in a Human Urine Model
10.1089/mdr.2020.0083 · doi-reference
Bacteriophage–Ciprofloxacin Combination Effectiveness Depends on Staphylococcus aureus–Candida albicans Dual-Species Communities’ Growth Model
10.1089/mdr.2021.0324 · doi-reference
Bacteriophages: A weapon against mixed-species biofilms in the food processing environment
10.1111/jam.15421 · doi-reference
Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh
10.1016/j.virol.2012.09.002 · doi-reference
Treatment of in vitro enterohemorrhagic Escherichia coli infection using phage and probiotics
10.1111/jam.13124 · doi-reference
10.3390/ani13081328
10.3390/ani13081328 · doi-reference
Advancing bacteriophages as a treatment of antibiotic-resistant bacterial pulmonary infections
10.1097/mcp.0000000000000864 · doi-reference
Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation—A proof-of-principle study in a P. aeruginosa lung infection model
10.1016/j.ejpb.2020.11.019 · doi-reference
The influence of external factors on bacteriophages—Review
10.1007/s12223-011-0039-8 · doi-reference
Achieving global targets for antimicrobial resistance
10.1126/science.aaf9286 · doi-reference
The next generation of bacteriophage therapy
10.1016/j.mib.2011.07.028 · doi-reference
Effects of Sequential and Simultaneous Applications of Bacteriophages on Populations of Pseudomonas aeruginosa In Vitro and in Wax Moth Larvae
10.1128/aem.00757-12 · doi-reference
Phage as a modulator of immune responses: Practical implications for phage therapy
10.1016/b978-0-12-394438-2.00002-5 · doi-reference
Bacteriophages ϕMR299-2 and ϕNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells
10.1128/mbio.00029-12 · doi-reference
Chestnut Honey and Bacteriophage Application to Control Pseudomonas aeruginosa and Escherichia coli Biofilms: Evaluation in an ex vivo Wound Model
10.3389/fmicb.2018.01725 · doi-reference
Combined treatment of Pseudomonas aeruginosa biofilms with bacteriophages and chlorine
10.1002/bit.24630 · doi-reference
Bacteriophage delivering hydrogels reduce biofilm formation in vitro and infection in vivo
10.1002/jbm.a.36790 · doi-reference
10.3390/v15051210
10.3390/v15051210 · doi-reference
CRISPR Immunity Drives Rapid Phage Genome Evolution in Streptococcus thermophilus
10.1128/mbio.00262-15 · doi-reference
Lytic and genomic properties of spontaneous host-range Kayvirus mutants prove their suitability for upgrading phage therapeutics against Staphylococci
10.1038/s41598-019-41868-w · doi-reference
JD419, a Staphylococcus aureus phage with a unique morphology and broad host range
10.3389/fmicb.2021.602902 · doi-reference
10.1371/journal.pone.0220421
10.1371/journal.pone.0220421 · doi-reference
Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus
10.1038/s41591-019-0437-z · doi-reference
Genetic engineering of bacteriophages against infectious diseases
10.3389/fmicb.2019.00954 · doi-reference
Engineering phage host-range and suppressing bacterial resistance through phage tail fiber mutagenesis
10.1016/j.cell.2019.09.015 · doi-reference
Engineered bacteriophage therapeutics: Rationale, challenges and future
10.1007/s40259-021-00480-z · doi-reference
Bacteriophages adhering to mucus provide a non-host-derived immunity
10.1073/pnas.1305923110 · doi-reference
PhageScore-based analysis of Acinetobacter baumannii infecting phages antibiotic interaction in liquid medium
10.1007/s00203-022-03020-7 · doi-reference
Rapid and quantitative automated measurement of bacteriophage activity against cystic fibrosis isolates of Pseudomonas aeruginosa
10.1111/j.1365-2672.2010.04928.x · doi-reference
10.1371/journal.pone.0004944
10.1371/journal.pone.0004944 · doi-reference